GLP-1 Secretion Is Increased by Inflammatory Stimuli in an IL-6-Dependent Manner, Leading to Hyperinsulinemia and Blood Glucose Lowering

Diabetes

Volumn 63, Issue 10, 2014, Pages 3221-3229

  Kahles, Florian ^a   Meyer, Christina ^a   Möllmann, Julia ^a   Diebold, Sebastian ^a   Findeisen, Hannes M ^a   Lebherz, Corinna ^a   Trautwein, Christian ^a   Koch, Alexander ^a   Tacke, Frank ^a   Marx, Nikolaus ^a   Lehrke, Michael ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; DIPEPTIDYL PEPTIDASE IV; ENDOTOXIN; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; INSULIN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; EXENDIN (9 39); EXENDIN (9-39); GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; LIPOPOLYSACCHARIDE; PEPTIDE FRAGMENT;

ADULT; AGED; ANIMAL EXPERIMENT; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CRITICALLY ILL PATIENT; CYTOKINE RELEASE; DISEASE SEVERITY; ENZYME INHIBITION; FEMALE; GLUCAGON BLOOD LEVEL; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; HUMAN TISSUE; HYPERINSULINEMIA; HYPOGLYCEMIA; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RELEASE; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; ADOLESCENT; ANIMAL; GENETICS; HYPERINSULINISM; KNOCKOUT MOUSE; METABOLISM; MIDDLE AGED; SECRETION (PROCESS); VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; BLOOD GLUCOSE; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPERINSULINISM; INFLAMMATION; INTERLEUKIN-1BETA; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MALE; MICE, KNOCKOUT; MIDDLE AGED; PEPTIDE FRAGMENTS; RECEPTORS, GLUCAGON; YOUNG ADULT;

EID: 84907481915     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db14-0100     Document Type: Article

References (41)

1. Turchin A, Matheny ME, Shubina M, Scanlon JV, Greenwood B, Pendergrass ML. Hypoglycemia and clinical outcomes in patients with diabetes hospitalized in the general ward. Diabetes Care 2009;32:1153-1157
2. Kosiborod M, Inzucchi SE, Goyal A, et al. Relationship between spontaneous and iatrogenic hypoglycemia and mortality in patients hospitalized with acute myocardial infarction. JAMA 2009;301:1556-1564
3. McAlister FA, Majumdar SR, Blitz S, Rowe BH, Romney J, Marrie TJ. The relation between hyperglycemia and outcomes in 2,471 patients admitted to the hospital with community-acquired pneumonia. Diabetes Care 2005;28:810-815
4. Kosiborod M, Inzucchi SE, Krumholz HM, et al. Glucometrics in patients hospitalized with acute myocardial infarction: defining the optimal outcomes-based measure of risk. Circulation 2008;117:1018-1027
5. Branco RG, Garcia PC, Piva JP, Casartelli CH, Seibel V, Tasker RC. Glucose level and risk of mortality in pediatric septic shock. Pediatr Crit Care Med 2005;6:470-472
6. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001;345:1359-1367
7. Finfer S, Chittock DR, Su SY, et al.; NICE-SUGAR Study Investigators. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009;360:1283-1297
8. Ling Y, Li X, Gao X. Intensive versus conventional glucose control in critically ill patients: a meta-analysis of randomized controlled trials. Eur J Intern Med 2012;23:564-574
9. Finfer S. Liu B. Chittock D.R. et al. NICE-SUGAR study investigators. Hypoglycemia and risk of death in critically ill patients N Engl J Med 2012 367 1108-1118 10
10. Finfer S, Liu B, Chittock DR, et al.; NICE-SUGAR Study Investigators. Hypoglycemia and risk of death in critically ill patients. N Engl J Med 2012;367:1108-1118 10. Jacobi J, Bircher N, Krinsley J, et al. Guidelines for the use of an insulin infusion for the management of hyperglycemia in critically ill patients. Grit Care Med 2012;40:3251-3276
11. Agwunobi AO, Reid C, Maycock P, Little RA, Carlson GL. Insulin resistance and substrate utilization in human endotoxemia. J Clin Endocrinol Metab 2000; 85:3770-3778
12. Van Cromphaut SJ, Vanhorebeek I, Van den Berghe G. Glucose metabolism and insulin resistance in sepsis. Curr Pharm Des 2008;14:1887-1899
13. Raetzsch CF, Brooks NL, Alderman JM, et al. Lipopolysaccharide inhibition of glucose production through the Toll-like receptor-4, myeloid differentiation factor 88, and nuclear factor kappa b pathway. Hepatology 2009;50:592-600
14. Lang CH, Dobrescu C. Sepsis-induced increases in glucose uptake by macrophage-rich tissues persist during hypoglycemia. Metabolism 1991;40: 585-593
15. Yelich MR, Filkins JP. Mechanism of hyperinsulinemia in endotoxicosis. Am J Physiol 1980;239:E156-E161
16. Vernay MC, Wellnitz O, Kreipe L, van Dorland HA, Bruckmaier RM. Local and systemic response to intramammary lipopolysaccharide challenge during long-term manipulated plasma glucose and insulin concentrations in dairy cows. J Dairy Sci 2012;95:2540-2549
17. Yelich MR. In vivo endotoxin and IL-1 potentiate insulin secretion in pancreatic islets. Am J Physiol 1990;258:R1070-R1077
18. Archer LT, White GL, Coalson JJ, Beller BK, Elmore O, Hinshaw LB. Preserved liver function and leukocyte response in superlethal endotoxic shock. Circ Shock 1978;5:279-289
19. Rayfield EJ, Curnow RT, Reinhard D, Kochicheril NM. Effects of acute endotoxemia on glucoregulation in normal and diabetic subjects. J Clin Endocrinol Metab 1977;45:513-521
20. Choy YM, Cheng CP, Luey LU, Loh SC, Fung KP, Lee CY. Endotoxin shock and tumour necrosis factor release in mannoheptulose-treated mice. Cancer Lett 1987;37:33-39
21. Blackard WG, Anderson JH Jr, Spitzer JJ. Hyperinsulinism in endotoxin shock dogs. Metabolism 1976;25:675-684
22. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007;132:2131-2157
23. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007;87: 1409-1439
24. Meier JJ, Nauck MA. Glucagon-like peptide 1 (GLP-1) in biology and pathology. Diabetes Metab Res Rev 2005;21:91-117
25. Meier JJ, Weyhe D, Michaely M, et al. Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes. Crit Care Med 2004;32:848-851
26. Nguyen AT, Mandard S, Dray C, et al. Lipopolysaccharides-mediated increase in glucose-stimulated insulin secretion: involvement of the GLP-1 pathway. Diabetes 2014;63:471-482
27. Drucker DJ, Jin T, Asa SL, Young TA, Brubaker PL. Activation of proglucagon gene transcription by protein kinase-A in a novel mouse enteroendocrine cell line. Mol Endocrinol 1994;8:1646-1655
28. Koch A, Voigt S, Kruschinski C, et al. Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients. Crit Care 2011;15:R63
29. Bone RC, Balk RA, Cerra FB, et al.; The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992;101:1644-1655
30. Durinx C, Lambeir AM, Bosmans E, et al. Molecular characterization of dipeptidyl peptidase activity in serum: soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides. Eur J Biochem 2000;267:5608-5613
31. Koch A, Gressner OA, Sanson E, Tacke F, Trautwein C. Serum resistin levels in critically ill patients are associated with inflammation, organ dysfunction and metabolism and may predict survival of non-septic patients. Crit Care 2009;13:R95
32. Abernathy CO, Bhathena SJ, Recant L, Zimmerman HJ, Utili R. Effects of acute and chronic endotoxin treatment on glucagon and insulin receptors on rat liver plasma membranes. Horm Metab Res 1982;14:468-471
33. Ellingsgaard H, Hauseimann I, Schuler B, et al. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med 2011;17:1481-1489
34. Salehi M, Prigeon RL, D'Alessio DA. Gastric bypass surgery enhances glucagon-like peptide 1-stimulated postprandial insulin secretion in humans. Diabetes 2011;60:2308-2314
35. Muscelli E, Mari A, Casolaro A, et al. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 2008;57:1340-1348
36. Yamaoka-Tojo M, Tojo T, Takahira N, et al. Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular disease. Cardiovasc Diabetol 2010;9:17
37. Piotrowski K, Becker M, Zugwurst J, et al. Circulating concentrations of GLP-1 are associated with coronary atherosclerosis in humans. Cardiovasc Diabetol 2013;12:117
38. Hattori A, Kawamura I, Yamada Y, et al. Elevated plasma GLP-1 levels and enhanced expression of cardiac GLP-1 receptors as markers of left ventricular systolic dysfunction: a cross-sectional study. BMJ Open 2013;3:e003201
39. Ku HC, Chen WP, Su MJ. GLP-1 signaling preserves cardiac function in endotoxemic Fischer 344 and DPP4-deficient rats. Naunyn Schmiedebergs Arch Pharmacol 2010;382:463-174
40. Kröller-Schön S, Knorr M, Hausding M, et al. Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition. Cardiovasc Res 2012;96:140-149
41. Dozier KC, Cureton EL, Kwan RO, Curran B, Sadjadi J, Victorino GP. Glucagon-like peptide-1 protects mesenteric endothelium from injury during inflammation. Peptides 2009;30:1735-1741